Related Experiment Video
Updated: Jul 16, 2026

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Prenylated p-Coumaric Acid Derivatives Mitigate Neurobehavioral and Neuroinflammatory Alterations Associated with
Camila A Cazarin1, Bruna Longo2, Eduarda R Bauer1
1Pharmaceutical Sciences Postgraduate Program, University of Vale do Itajaí, Itajaí 88302901, SC, Brazil.
None:
Inflammatory bowel disease is an inflammatory disorder associated with systemic immune activation, contributing to neuroinflammation, behavioral impairments and disruption of the gut-brain axis. The present study investigated the effects of p-Coumaric acid derivatives: Artepillin C (ART-C), Baccharin (BAC), and Drupanin (DRU) on colonic damage, behavioral alterations, and oxidative stress in a dextran sulfate sodium (DSS)-induced colitis by administration of 3% DSS. Mice were treated with p-Coumaric acid derivatives (0.3, 1, or 3 mg/kg, p.o.), and disease activity index and colon length were evaluated as clinical parameters. Behavioral assessments included the open field test, novel object recognition test, elevated plus maze, and tail suspension test. Oxidative stress and inflammatory markers were quantified in colon, serum, cortex, and hippocampus, alongside histological analysis of colonic tissue. DSS administration induced clinical and histopathological alterations, increased oxidative stress, and impaired recognition memory, as well as anxiety- and depressive-like behaviors. p-Coumaric acid derivatives attenuated colonic damage, preserved tissue architecture, improved recognition memory, and reduced anxiety- and depressive-like behaviors, particularly at higher doses. These effects were associated with modulation of antioxidant defenses and reduction of lipid peroxidation and inflammatory markers. p-Coumaric acid derivatives exert protective effects in DSS-induced colitis, highlighting their potential as therapeutic agents for intestinal and neurobehavioral alterations associated with IBD.
More Related Videos
08:34Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...